We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02536742
Previous Study | Return to List | Next Study

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer (PYTHIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02536742
Recruitment Status : Unknown
Verified February 2021 by ETOP IBCSG Partners Foundation.
Recruitment status was:  Active, not recruiting
First Posted : September 1, 2015
Last Update Posted : February 15, 2021
Breast International Group
Information provided by (Responsible Party):
ETOP IBCSG Partners Foundation

Brief Summary:
This international, multicenter, prospective single arm Phase II biomarker discovery clinical trial with the primary objective of assessing the association of PFS with gene mutations, gene copy number aberrations and gene signatures in post-menopausal women with hormone receptor positive, HER2-negative metastatic or locally relapsed breast cancer whose disease has progressed after prior adjuvant endocrine therapy or one line systemic treatment, i.e., endocrine treatment or chemotherapy, administered for metastatic disease.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Palbociclib Drug: Fulvestrant Phase 2

Detailed Description:

Patients will be treated with the combination of palbociclib and fulvestrant. The primary objective is to assess the association of the primary endpoint progression-free survival (PFS) with potential markers.

The trial is included in the AURORA program conducted by the Breast International Group (BIG), an international study aiming to collect and characterize biological samples, including metastatic tissue, from patients with advanced breast cancer.

The primary aim of the PYTHIA study is to discover potentially innovative biomarkers for the selection of patients to Palbociclib/Fulvestrant treatment. The strength of the trial lies in its conduct in conjunction with the AURORA study, which systematically evaluates a panel of biomarkers in tissue and blood, in a certified central lab. Stemming from this association, an abundance of molecular profiling information will become available for different biological samples. Additional molecular and functional imaging assessments performed within the context of the PYTHIA study increase its scientific merit, since it will represent a prospective, systematic effort to identify biomarkers for patient stratification, integrating several molecular profiling assessments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 124 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer
Actual Study Start Date : August 30, 2016
Actual Primary Completion Date : August 28, 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Experimental
Palbociclib plus Fulvestrant
Drug: Palbociclib
125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
Other Names:
  • PD-0332991
  • Ibrance

Drug: Fulvestrant
500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
Other Name: Faslodex

Primary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Maximal 36 months ]
    Time from treatment initiation until documented disease progression according to RECIST 1.1 or death, whichever occurs first

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female gender
  • Age ≥ 18 years
  • Postmenopausal, defined as women with:

    • Prior bilateral surgical oophorectomy; or
    • Amenorrhea and age ≥ 60 years; or
    • Age < 60 years and amenorrhea for 12 or more consecutive months in the absence of alternative pathological or physiological cause and FSH and serum estradiol levels within the laboratory's reference ranges for postmenopausal women.
  • Endocrine resistant disease, defined as one of:

    • Relapse while on adjuvant endocrine therapy;
    • Relapse within 12 months after completion of adjuvant endocrine therapy;
    • Progression of disease under first line endocrine therapy for metastatic and/or loco-regionally advanced breast cancer.

Note: Patient may have received one prior chemotherapy for advanced or metastatic breast cancer.

  • ER positive tumor and HER2-negative tumor, as assessed locally
  • ECOG Performance Status 0-1.
  • Measurable or non-measurable but evaluable disease according to RECIST 1.1.
  • Written Informed Consent (IC) for screening procedures.
  • Written informed consent to participate in the AURORA program of BIG.
  • The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
  • Life expectancy >3 months.
  • Hematological status:

    • Absolute neutrophil count ≥ 1.5 × 109/L
    • Platelet count ≥ 100 × 109/L
    • Hemoglobin ≥ 9 g/dL
  • Hepatic status:

    • Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN).
    • AST and ALT ≤ 2.5 × ULN; if the patient has liver metastases, ALT and AST must be ≤ 5 × ULN.
  • Glucose in normal range, or well-controlled diabetes defined as an HbA1c level ≤ 7.5%.
  • Renal status:

    - Creatinine ≤ 1.5 ×ULN or creatinine clearance > 60 ml/min.

  • International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant.
  • Ability to swallow oral medication.

Exclusion Criteria:

  • Prior use of fulvestrant or any CDK inhibitor.
  • More than one prior line of chemotherapy for metastatic or locally relapsed disease.
  • Previous or current non-breast malignancies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.
  • Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth.
  • Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (NYHA functional classification ≥3), cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
  • QTc exceeding 480msec, family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP).
  • Uncontrolled electrolyte disorders that can reinforce the QT-prolonging effect of the drug (e.g., hypocalcemia, hypokalemia, hypomag¬nesemia).
  • Known history of HIV seropositivity. HIV screening is not required at baseline.
  • Uncontrolled diabetes defined as HbA1c level > 7.5%.
  • Concurrent disease or familial, sociological or geographical condition that would make the patient inappropriate for trial participation or any serious medical disorder that would interfere with the patient's safety.
  • Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of Informed Consent.
  • Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular injections of fulvestrant.
  • Treatment with an investigational agent in the 4 weeks before enrollment.
  • Concurrent treatment with any of the drugs not permitted
  • Adverse events (except alopecia) from previous systemic cancer therapy, radiotherapy or surgery have not recovered to CTCAE v4.0 grade 1 or resolved prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02536742

Show Show 19 study locations
Sponsors and Collaborators
ETOP IBCSG Partners Foundation
Breast International Group
Layout table for investigator information
Study Chair: Luca Malorni, MD PhD USL4 Hospital of Prato, Italy
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ETOP IBCSG Partners Foundation
ClinicalTrials.gov Identifier: NCT02536742    
Other Study ID Numbers: IBCSG 53-14 / BIG 14-04
2014-005387-15 ( EudraCT Number )
WI198393 ( Other Identifier: Pfizer number )
First Posted: September 1, 2015    Key Record Dates
Last Update Posted: February 15, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ETOP IBCSG Partners Foundation:
Breast Cancer
HER2 negative
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action